CHATSWORTH, Calif., Feb. 17, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), at the American Society for Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium in Orlando, FL, today presented an abstract of the results of a multi-center clinical study utilizing its proprietary NADiA®ProsVue™ prognostic prostate cancer test in 392 post-radical prostatectomy patients with PSA levels below 100 pg/mL (picogram per milliliter). In the clinical study, IRIS’s proprietary ultra-sensitive NADiA ProsVue prostate cancer test was able to quantify PSA levels in all patient samples, with an initial median value for stable patients of 2.7 pg/mL, undetectable by the most sensitive FDA cleared assays currently available.
